Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Neurocrine Biosciences (NBIX) over the last 15 years, with Q4 2025 value amounting to $372.8 million.

  • Neurocrine Biosciences' Net Cash Flow rose 42193.44% to $372.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $480.0 million, marking a year-over-year increase of 275193.37%. This contributed to the annual value of $480.0 million for FY2025, which is 275193.37% up from last year.
  • Per Neurocrine Biosciences' latest filing, its Net Cash Flow stood at $372.8 million for Q4 2025, which was up 42193.44% from $76.4 million recorded in Q3 2025.
  • In the past 5 years, Neurocrine Biosciences' Net Cash Flow ranged from a high of $372.8 million in Q4 2025 and a low of -$256.6 million during Q2 2024
  • Moreover, its 4-year median value for Net Cash Flow was $69.7 million (2025), whereas its average is $47.3 million.
  • In the last 5 years, Neurocrine Biosciences' Net Cash Flow crashed by 55335.69% in 2024 and then soared by 42193.44% in 2025.
  • Over the past 4 years, Neurocrine Biosciences' Net Cash Flow (Quarter) stood at $165.5 million in 2021, then crashed by 125.92% to -$42.9 million in 2023, then plummeted by 169.93% to -$115.8 million in 2024, then skyrocketed by 421.93% to $372.8 million in 2025.
  • Its Net Cash Flow was $372.8 million in Q4 2025, compared to $76.4 million in Q3 2025 and $69.7 million in Q2 2025.